TY - JOUR
T1 - Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer
AU - Bishop, J. F.
AU - Raghavan, D.
AU - Stuart-Harris, R.
AU - Morstyn, G.
AU - Aroney, R.
AU - Kefford, R.
AU - Yuen, K.
AU - Lee, J.
AU - Gianoutsos, P.
AU - Olver, I. N.
AU - Zalcberg, J.
AU - Ball, D.
AU - Bull, C.
AU - Fox, R.
PY - 1987
Y1 - 1987
N2 - The efficacy and toxicity of carboplatin 100 mg/m2, administered intravenously (IV) daily x 3, and VP-16-213 120 mg/m2, IV daily x 3, administered every 28 days for six courses, was assessed in 94 (36 limited stage, 58 extensive stage) previously untreated patients with small-cell lung cancer. Mediastinal irradiation using 50 Gy in 25 fractions was given to all limited-stage patients with a complete (CR) or partial response (PR) after three chemotherapy courses. Cranial irradiation was administered to all patients with CR. Objective responses were seen in 77% (CR 40%, PR 37%) of patients with limited-stage and 58% (CR, 9%; PR, 49%) with extensive-stage disease. Median relapse-free survival for objective responders with limited stage was 14.6 months and 7.9 months for extensive-stage patients. Median relapse-free survival following CR was 15.4 months and 8.5 months for PR. Median survival was 15.3 months for limited-stage and 8.1 months for extensive-stage patients. The combination was well tolerated with mild nausea or less (World Health Organization [WHO] grade 0 or 1) in 62% of patients and minimal mucositis, renal, neurotoxicity, or ototoxicity. Neutropenia <1.0 x 109/L (WHO grade 3 or 4) was seen in 63% of patients, with two deaths from infection while neutropenic. The combination of carboplatin and VP-16-213 is a new, active program with low toxicity when applied intensively in previously untreated patients with small-cell lung cancer.
AB - The efficacy and toxicity of carboplatin 100 mg/m2, administered intravenously (IV) daily x 3, and VP-16-213 120 mg/m2, IV daily x 3, administered every 28 days for six courses, was assessed in 94 (36 limited stage, 58 extensive stage) previously untreated patients with small-cell lung cancer. Mediastinal irradiation using 50 Gy in 25 fractions was given to all limited-stage patients with a complete (CR) or partial response (PR) after three chemotherapy courses. Cranial irradiation was administered to all patients with CR. Objective responses were seen in 77% (CR 40%, PR 37%) of patients with limited-stage and 58% (CR, 9%; PR, 49%) with extensive-stage disease. Median relapse-free survival for objective responders with limited stage was 14.6 months and 7.9 months for extensive-stage patients. Median relapse-free survival following CR was 15.4 months and 8.5 months for PR. Median survival was 15.3 months for limited-stage and 8.1 months for extensive-stage patients. The combination was well tolerated with mild nausea or less (World Health Organization [WHO] grade 0 or 1) in 62% of patients and minimal mucositis, renal, neurotoxicity, or ototoxicity. Neutropenia <1.0 x 109/L (WHO grade 3 or 4) was seen in 63% of patients, with two deaths from infection while neutropenic. The combination of carboplatin and VP-16-213 is a new, active program with low toxicity when applied intensively in previously untreated patients with small-cell lung cancer.
UR - http://www.scopus.com/inward/record.url?scp=0023472047&partnerID=8YFLogxK
M3 - Article
C2 - 2821197
AN - SCOPUS:0023472047
SN - 0732-183X
VL - 5
SP - 1574
EP - 1578
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 10
ER -